tbuckley/cabot-search huggingface dataset:
Bortezomib and High-Dose Melphalan as a Novel Conditioning Regimen for Patients with POEMS Syndrome Undergoing Autologous Peripheral Blood Stem Cell Transplantation.
Authors: XiaoWen Tang, Xiaolan Shi, Xiaohui Hu, Shengli Xue, Huiying Qiu, Yue Han, Lingzhi Yan, Huifen Zhou, Yuejun Liu, Bin Gu, Aining Sun, Wu Depei
Journal: Blood (2010)
High Rate of Engraftment and Low Regimen-Related Toxicity Using Fludarabine, Melphalan and Thiotepa Conditioning for Unrelated Donor Cord Blood Transplantation
Authors: Stefan O Ciurea, Partow Kebriaei, Issa F Khouri, Muzaffar H. Qazilbash, Roy B Jones, Demetrios Petropoulos, Laura L. Worth, Amin M Alousi, Chitra M Hosing, Poliana Patah, Pedro Cano, John McMannis, Sergio A Giralt, Marcelo Fernandez-Vina, Richard E Champlin, Elizabeth J. Shpall, Marcos De Lima
Journal: Blood (2008)
End of life (EOL) chemotherapy (CT) in gastro-intestinal (GI) cancer patients (pts): A retrospective AGEO study
Authors: A. Lapeyre-Prost, G. Perkins, M. Vallee, A. Pozet, D. Tougeron, M. Maillet, C. Locher, J. Dreanic, J.L. Legoux, A. Lievre, C. Lecaille, J.-M. Sabate, F. Mary, F. Bonnetain, H. Jaulmes-Bouillot, B. Landi, J. Taieb
Journal: Annals of Oncology (2016)
Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL
Authors: Christopher J Walker, Joshua J Oaks, Ramasamy Santhanam, Paolo Neviani, Jason G Harb, Gregory Ferenchak, Justin Ellis, Guido Marcucci, Yosef Landesman, Sharon Shacham, Michael Kauffman, Danilo Perrotti
Journal: Blood (2012)
Molecular Characterization of Cytotoxic T Cell Repertoire in Aplastic Anemia and Myelodysplastic Syndromes
Authors: Sofie Alexandra Lundgren, Mikko A Keränen, Paula Savola, Giljun Park, Freja Ebeling, Gunilla Walldin, Eva Hellström-Lindsberg, Satu Mustjoki
Journal: Blood (2016)
Rapid emergence of <i>Mycobacterium tuberculosis</i> bedaquiline resistance: lessons to avoid repeating past errors
Authors: Nicolas Veziris, Christine Bernard, Lorenzo Guglielmetti, Damien Le Du, Dhiba Marigot-Outtandy, Marie Jaspard, Eric Caumes, Isabelle Lerat, Christophe Rioux, Yazdan Yazdanpanah, Angelica Tiotiu, Nadine Lemaitre, Florence Brossier, Vincent Jarlier, Jerome Robert, Wladimir Sougakoff, Alexandra Aubry
Journal: European Respiratory Journal (2016)

Bedaquiline (BDQ) has demonstrated potent clinical activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis complex strains [1–3]. It has now been used in >50 countries, and it is estimated that ∼2500 patients had been treated with BDQ by the end of 2015. In spite of its recent clinical use, there are few reports of BDQ-resistant strains [4, 5]. Mutations in the rv0678 gene encoding the MmpL5 efflux pump repressor generate low-level BDQ resistance and clofazimine (CFZ) cross-resistance [6]. To our knowledge, this is the sole mechanism of BDQ resistance described in clinical strains [4, 5]. Despite its introduction in France in 2011 for XDR- and MDR-tuberculosis (TB) treatment, we report herein four BDQ-resistant cases, and discuss strategies to avoid a surge of BDQ resistance. Bedaquiline resistance appears rapidly both after treatment and in patients that have never been treated <http://ow.ly/mxEM30604OF> The members of CNR MyRMA (Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux) are as follows: Emmanuelle Cambau, Laurent Raskine and Faïza Mougari (Assistance Publique Hôpitaux de Paris, Hôpitaux Universitaires Lariboisière-Saint Louis, Service de Bactériologie, Centre National de Référence des Mycobactéries et Résistance des Mycobactéries aux Antituberculeux (CNR-MyRMA), IAME, UMR 1137, INSERM, Univ Paris Diderot, Sorbonne Paris Cité, Paris, France). The members of the Tuberculosis consilium of the CNR MyRMA are as follows: Claire Andrejak (Service de Pneumologie et de Réanimation Respiratoire, CHU Sud, Amiens, France), Mathilde Fréchet-Jachym (Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges, France), Guillaume Thouvenin (Service de Pneumologie Pédiatrique, Hôpital Armand Trousseau, Assistance Publique Hôpitaux de Paris (AP-HP), Centre National de Référence des Maladies Respiratoires Rares RespiRare, Paris, France and Inserm UMRS928, Université Pierre et Marie Curie, Sorbonne Universités, Paris), Katarina Chadelat (Hôpital d'Enfants Armand-Trousseau, AP-HP, Paris), Bertrand Dautzenberg (Hôpitaux Universitaires Pitié-Salpêtrière-Charles-Foix, AP-HP, Université Pierre-et-Marie-Curie, Paris), Najoua Helali (Clinical Microbiology Unit, Saint-Joseph Hospital Network, Paris) and Bénedictine Rivoire (Samu Social, Paris).
Autonomic Modulation and Contact System in Patients with Hereditary Angioedema Due to C1 Inhibitor Deficiency
Authors: Maddalena Alessandra Wu, Francesca Perego, Nada Afifi Afifi, Chiara Suffritti, Andrea Zanichelli, Antonio Gidaro, Liliane Appratto de Souza, Eleonora Tobaldini, Nicola Montano, Marco Cicardi
Journal: Journal of Allergy and Clinical Immunology (2017)
P21.01 Primary intracranial round cell sarcoma in an HIV patient: a case report
Authors: M. A. Sales, J. Pascual
Journal: Neuro-Oncology (2016)

Primary intracranial sarcoma among patients diagnosed with HIV is rare. Case reports published have shown that there is an increasing number of cases of leiomyosarcoma, hemangiopericytoma and rhabdomyosarcoma among these patients. Further, there are also few reports that sarcomas may present atypically, sometimes mimicking a brain abscess. We report a case of a 26 year old male, newly diagnosed HIV, who presented with bilateral chronic suppurative otitis media associated fever, headache and vomiting. Neuroimaging showed with multiple rim enhancing masses on the left temporal, parietal and occipital areas and bilaterally sclerosed mastoid air cells. Initial impression was an otogenic abscess. Burrhole craniotomy and evacuation of the cystic masses was done. Histopathologic examination revealed a small round blue cell sarcoma. Different immunostains were done to differentiate the various subtypes of sarcomas possible. Patient was discharged improved but did not consent to chemotherapy or radiotherapy. Also, we present a review of literature of the different primary intracranial sarcomas among patients diagnosed with HIV.
PDCT-11. QUANTITATIVE TRACKING OF T-CELL CLONES AFTER ADOPTIVE CELLULAR THERAPY TARGETING RECURRENT MEDULLOBLASTOMA USING MASSIVELY PARALLEL RNA SEQUENCING TECHNOLOGY
Authors: Oleg Yegorov, Anjelika Dechkovskaia, Marcia Hodik, Jianping Huang, Elias Sayour, Sridharan Gururangan, Duane Mitchell
Journal: Neuro-Oncology (2016)

Adoptive cellular therapy (ACT) using transfer of tumor-specific lymphocytes has emerged as a potent strategy for treatment of advanced and refractory malignancies. We have established a novel next-generation sequencing approach based on comprehensive characterization of the T-cell receptor (TCR) repertoire changes in patients with recurrent medulloblastoma and PNETs undergoing adoptive cellular therapy at our center (Re-MATCH protocol, FDA IND BB-14058). Total RNA was isolated from patient PBMC samples collected prior to adoptive cellular therapy and weekly for one month and then 5 months following immunotherapy treatment. cDNA was generated with addition of a common adapter at 5’ end of cDNA using SMART technology. PCR was performed to amplify TCR alpha and beta chains and included adapter and index sequences compatible with the Illumina sequencing platform. Libraries were sequenced on Illumina MiSeq using 600 cycle reagent kit with paired end, 300 + 300 base pair reads. T-cell sequences were analyzed using MiXCR software package, hosted on BaseSpace, Illumina’s cloud computing environment. The observed sequence reads in the peripheral blood allowed us to identify 54 TCRAV and 64 TCRBV exons which indicated a good coverage of TCR genes by our cDNA sequencing approach. The data revealed that certain T-cells were clonally expanded after ACT, with an increasing number of “hyper-expanded” TCR clones (comprising >1% of all TCR beta or alpha sequences) after adoptive cellular therapy. These TCR clones established a new balance in the peripheral blood that was stable over the next 5 months following the completion of cellular immunotherapy. This new method is useful for routine monitoring of clonotypic TCR expansion in the peripheral blood of patients undergoing immunotherapy, requires low blood sample volume, and may significantly enhance capacity to monitor the response to immunotherapy in patients with brain tumors.
Correlative Analysis of T Cell Subpopulations and CD20 Expression In a Phase II Study of Lenalidomide In Combination with Rituximab In Patients with Relapsed or Refractory CLL/SLL
Authors: Marays Veliz, John Powers, Ling Zhang, Enrique Santana, Jeffrey E. Lancet, Rami S. Komrokji, Mohamed Kharfan-Dabaja, Sara Tinsley, Darcie Deaver, Eduardo M. Sotomayor, Javier Pinilla-Ibarz
Journal: Blood (2010)
Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes
Authors: Andrew P. Ambrosy, Lukasz P. Cerbin, Paul W. Armstrong, Javed Butler, Adrian Coles, Adam D. DeVore, Mark E. Dunlap, Justin A. Ezekowitz, G. Michael Felker, Marat Fudim, Stephen J. Greene, Adrian F. Hernandez, Christopher M. O'Connor, Philip Schulte, Randall C. Starling, John R. Teerlink, Adriaan A. Voors, Robert J. Mentz
Journal: JACC Heart Failure (2016)
Omics Approaches to Identify Potential Biomarkers of Inflammatory Diseases in the Focal Adhesion Complex
Authors: Johanne Brooks, Alastair Watson, Tamas Korcsmaros
Journal: Genomics Proteomics & Bioinformatics (2017)

Inflammatory diseases such as inflammatory bowel disease (IBD) require recurrent invasive tests, including blood tests, radiology, and endoscopic evaluation both to diagnose and assess disease activity, and to determine optimal therapeutic strategies. Simple 'bedside' biomarkers could be used in all phases of patient management to avoid unnecessary investigation and guide further management. The focal adhesion complex (FAC) has been implicated in the pathogenesis of multiple inflammatory diseases, including IBD, rheumatoid arthritis, and multiple sclerosis. Utilizing omics technologies has proven to be an efficient approach to identify biomarkers from within the FAC in the field of cancer medicine. Predictive biomarkers are paving the way for the success of precision medicine for cancer patients, but inflammatory diseases have lagged behind in this respect. This review explores the current status of biomarker prediction for inflammatory diseases from within the FAC using omics technologies and highlights the benefits of future potential biomarker identification approaches.
GlycoVariant Anti-CD37 Small Modular Immuno-Pharmaceutical Exhibits Superior Natural Killer Cell Mediated Cytotoxicity Against Chronic Lymphocytic Leukemia Cells at Low Concentrations and Low Antigen Density
Authors: Sarwish Rafiq, Carolyn M Cheney, Gerard Lozanski, Rosa Lapalombella, Xiaokui Mo, Anthony Siadak, David Jarjoura, John C. Byrd, Natarajan Muthusamy
Journal: Blood (2010)
Hepatic adenoma among adult survivors of childhood cancer.
Authors: Emily S. Tonorezos, Dana Barnea, Ghassan K. Abou-Alfa, Jacqueline Bromberg, Michael Ian D'Angelica, Charles A. Sklar, Kevin C. Oeffinger
Journal: Journal of Clinical Oncology (2016)

117 Background: Hepatic adenoma is a rare and poorly understood benign epithelial neoplasm. Because of the potential for spontaneous hemorrhage, rupture, or malignant transformation; hepatic adenoma over 5 cm require resection. In the general population, the prevalence of hepatic adenoma is estimated at 1 in 100,000 and identified predominantly in obese females on oral contraceptives. An increased risk for hepatic adenoma among adult survivors of childhood and young adult cancer has not been previously reported Methods: Cancer diagnosis and treatment, as well as demographic factors, medications, and comorbidities, were collected from the medical chart among patients with pathological confirmation of hepatic adenoma. All cases were patients diagnosed with a non-hepatic cancer before the age of 40 and seen at Memorial Sloan Kettering Cancer Center. Results: Twelve cases of hepatic adenoma were pathologically confirmed; seven patients (58%) had more than one adenoma. Eleven (92%) cases were female. The most common preceding cancer diagnosis was leukemia (N = 4; 33%). Five (42%) had undergone allogeneic hematopoietic cell transplant with total body irradiation (TBI) as part of their preconditioning regimen. Cases were not as a rule obese; median body mass index was 22.2 kg/m 2 (range, 17.6-31.0 kg/m 2 ). All eleven females had a history of current or prior hormone therapy with estrogen and progesterone; the single male case was hypogonadal as a result of radiation therapy to the testes during treatment for acute myelogenous leukemia (AML) and was receiving testosterone therapy at the time of chart review. Eight patients (67%) had hypothyroidism and two (17%) were taking anti-epileptic drugs. Only two patients (17%) were monitored radiographically following biopsy; seven patients (58%) underwent hepatic resection and three (25%) underwent embolization. No patient had significant blood loss or has been observed to undergo malignant transformation, although follow-up is ongoing. Conclusions: Adult survivors of childhood and young adult cancer, particularly females with a history of current or prior hormone therapy, may be at increased risk for hepatic adenoma. Further investigation of this potentially morbid condition is warranted.
6P Quinazoline clubbed s-triazine derivatives as VEGFR2 kinase inhibitor: Design, synthesis, docking, antiproliferative and antiangiogenic activity on cancer-induced chick embryo
Authors: A. Verma, P. Pathak, P.K. Shukla, V. Kumar, A. Kumar, A.K. Singh
Journal: Annals of Oncology (2016)
Busulfan Dosing May Affect Survival Following Reduced Intensity Stem Cell Transplantation in Patients with Acute Myelogeneous Leukemia.
Authors: Karen K Ballen, Steven L McAfee, Bimalangshu R Dey, Christine Dube, Eyal C Attar, Yi-Bin Chen, Philip C Amrein, Thomas R Spitzer
Journal: Blood (2009)
274TiP A randomized phase 2 study of nanoliposomal irinotecan (nal-IRI, BAX2398)-containing regimen in Japanese patients with metastatic pancreatic adenocarcinoma (mPAC)
Authors: T. Ioka, M. Ueno, H. Ueno, S. Kabir, T. Tokudome, M. Ikeda
Journal: Annals of Oncology (2016)
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
Authors: Tomas Kalincik, J William L Brown, Neil Robertson, Mark Willis, Neil Scolding, Claire M Rice, Alastair Wilkins, Owen Pearson, Tjalf Ziemssen, Michael Hutchinson, Christopher McGuigan, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Raed Alroughani, Eugenio Pucci, Patrizia Sola, Raymond Hupperts, Jeannette Lechner-Scott, Murat Terzi, Vincent Van Pesch, Csilla Rozsa, François Grand'Maison, Cavit Boz, Franco Granella, Mark Slee, Daniele Spitaleri, Javier Olascoaga, Roberto Bergamaschi, Freek Verheul, Steve Vucic, Pamela McCombe, Suzanne Hodgkinson, Jose Luis Sanchez-Menoyo, Radek Ampapa, Magdolna Simo, Tunde Csepany, Cristina Ramo, Edgardo Cristiano, Michael Barnett, Helmut Butzkueven, Alasdair Coles
Journal: The Lancet Neurology (2017)
Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study
Authors: Vinod S Hegade, Stuart F W Kendrick, Robert L Dobbins, Sam R Miller, Douglas Thompson, Duncan Richards, James Storey, George E Dukes, Margaret Corrigan, Ronald P J Oude Elferink, Ulrich Beuers, Gideon M Hirschfield, David E Jones
Journal: The Lancet (2017)
Cytomegalovirus (CMV) DNA load in breast milk of human immunodeficiency virus-positive women and infant CMV infection acquisition are not reduced with long-term antiretroviral therapy
Authors: M. Giuliano, M.F. Pirillo, G. Liotta, M. Andreotti, M. Floridia, F. Ciccacci, H. Jere, J.-B. Sagno, R. Amici, S. Mancinelli, M.C. Marazzi, S. Vella, L. Palombi
Journal: Clinical Microbiology and Infection (2017)
Critical role of IRF1 and BATF in forming chromatin landscape during type 1 regulatory cell differentiation
Authors: Katarzyna Karwacz, Emily R Miraldi, Maria Pokrovskii, Asaf Madi, Nir Yosef, Ivo Wortman, Xi Chen, Aaron Watters, Nicholas Carriero, Amit Awasthi, Aviv Regev, Richard Bonneau, Dan Littman, Vijay K Kuchroo
Journal: Nature Immunology (2017)
Minimal Residual Disease Monitoring By 8-Color Flow Cytometry in Mantle Cell Lymphoma Is Complementary to Q-PCR Monitoring and Will Facilitate Pre-Emptive Treatment: An EU-MCL and Lysa Study
Authors: Morgane Cheminant, Stephanie Schmit, Aurore Touzart, Coralie Derrieux, Marie-Hélène Delfau-Larue, Catherine Thieblemont, Vincent Ribrag, Loic Ysebaert, Fabrice Jardin, Stephane Cheze, Francois Lefrère, Richard Delarue, Christiane Pott, Eva Hoster, Martin Dreyling, Vahid Asnafi, Olivier Hermine, Elizabeth Macintyre
Journal: Blood (2014)
Inter-ethnic variability of S-1 pharmacokinetics (PK) and correlation with CYP2A6 phenotyping
Authors: B. C. Goh, R. A. Soo, S. Lim, J. Zhang, T. Furuie, P. D. Urrea, L. S. Rosen
Journal: Journal of Clinical Oncology (2008)

2507 Background: S-1 is an oral fixed combination drug composed of a prodrug of 5-FU (tegafur [FT]), a dihydropyrimidine dehydrogenase inhibitor (gimeracil [CDHP]), and an inhibitor primarily in the lower GI tract of 5-FU phosphorylation (Oxo). FT is primarily converted to 5-FU via CYP2A6. The purpose of this study was to compare S-1 PK and CYP2A6 activity of Asian and Caucasian patients. Methods: Asian and Caucasian patients with advanced solid tumors were enrolled in Singapore and the US and received S-1 30 mg/m2 bid for 14 consecutive days every 3 weeks. Blood samples for determination of S-1 components and metabolites were collected on Day 14 of cycle 1 at 0, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 30 and 48 hrs post-dose. CYP2A6 activity was determined using ratio of plasma cotinine and nicotine concentrations after chewing nicotine gum. Results: Of 18 Asian (15 Chinese, 3 Malay) and 19 Caucasian patients enrolled, 11 Asian and 10 Caucasian patients with mean BSA 1.63 m2 and 1.89 m2, respectively, were evaluable for PK. Results are shown in the table. The most common treatment-related G3/4 AEs were diarrhea and/or dehydration in 4 Caucasian patients (21%); no treatment-related G3/4 AEs were reported in Asian patients. Conclusions: Although not statistically significant, Asians had higher FT and lower 5-FU exposure as compared to Caucasians, consistent with the lower CYP2A6 activity observed in Asian patients. While S-1 was well tolerated in both populations, GI toxicities were more common in Caucasian patients, possibly from ethnic differences in FT activation and Oxo absorption in the GI tract. Analyte Parameters Geometric Mean Ratio of Geometric Means Asian (n=11) Caucasian (n=10) Point Estimate (90% CI) FT AUC(0- 12h) 24122 19171 1.26 (0.96, 1.64) Cmax 3113 2828 1.10 (0.86, 1.42) 5-FU AUC(0–12h) 687 786 0.87 (0.65, 1.18) Cmax 139 152 0.91 (0.67, 1.24) CDHP AUC(0–12h) 1714 1406 1.22 (0.99, 1.50) Cmax 416 284 1.47 (1.11, 1.94) Oxo AUC(0–12h) 230 460 0.50 (0.25, 0.98) Cmax 46 85 0.55 (0.27, 1.12) CYP 2A6 activity Cotinine/nicotine ratio 2.21* 3.66 0.60 (0.39, 0.94) * n=10 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Taiho Taiho
Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT).
Authors: Yago Nieto, Nizar M. Tannir, Shi-Ming Tu, Roy B. Jones, Amado J. Zurita, Ana Aparicio, Roland Bassett, Kim Allyson Margolin, Leona Holmberg, Richard E. Champlin, Lance C. Pagliaro
Journal: Journal of Clinical Oncology (2012)

4533 Background: HDC is a curative therapy for relapsed GCT. However, multiple prior relapses, cisplatin refractoriness (relapse/progression (PD) within 4 weeks) or absolute refractoriness (no prior response), or very high tumor markers at relapse predict poor early event-free survival (EFS). The validated Beyer model (JCO 1996;14:2638) identifies groups with poor risk (5% EFS at 1-year post-HDC), intermediate risk (25% EFS) or good risk (≥50% EFS). Given high VEGF expression in metastatic GCT and synergy between BEV and chemotherapy, we studied concurrent BEV/HDC in refractory GCT. Methods: Eligibility includes ≥ 1 st relapse/PD, poor/interm risk and no contraindications to HDC or BEV. Treatment consisted of 2 cycles of HDC with stem-cell support following BEV (5 mg/kg) 1 week before each cycle. HDC-1 consists of a novel regimen of infusional gemcitabine with docetaxel/melphalan/carboplatin (BBMT 2005;11:297). HDC-2 includes ifosfamide/carboplatin/etoposide. Target accrual is 25 pts, to distinguish a 1-yr expected EFS of 15% (median time to progression [TTP], 9 months) from 50% 1-year EFS (median TTP, 2 years). Results: 21 pts have been treated, median age 22 (range, 19-45) poor risk (N=15) or interm risk (N=6), cisplatin refractoriness (N=9) or absolute refr (N=12), median 3 prior relapses (1-4), median 3 prior regimens (2-6), PD at HDC: 11 pts. Tumor sites: lungs (N=15), liver (8), bones (5), brain (5), retroperit (15), mediast (12). Histol at Dx: embryonal ca (4), chorio (3), mixed with teratoma (14). Prior surgery for metastases: 8 pts (6 abdomen, 1 liver, 1 brain). Prior radiation: 6 pts. Toxicity of HDC-1: grade 3 mucositis in all pts, rash (8 G2, 2 G3) and transaminase elevation; 2 pts with marginal baseline renal function died from early sepsis; 1 pt died from late fungal pneumonia. After HDC-1, markers normalized in 14/17 evaluable pts. 15 pts received HDC-2 at a median 49 (38-66) days after 1 st stem cell infusion, which was well tolerated. 8 pts had residual lesions resected with findings of either teratoma (N=2) or no viable tumor (N=6). With median follow-up of 23 (3-43) months, 14 pts are alive in CR (67% EFS). Conclusions: BEV with HDCx2 shows encouraging preliminary results in heavily pretreated refractory GCT.
Treament options in advanced castration-resistant, docetaxel-resistant prostate cancer (acrdrpc). final results of a network meta-analysis
Authors: C. Cherubini, E. Bianchi, F. Montanari, E. Tamburini, M. Fantini, C. Ridolfi, C. Santelmo, S.L.V. Nicoletti, G. Pasini, L. Stocchi, D. Tassinari
Journal: Annals of Oncology (2016)
Acute attacks in patients with Hereditary Angioedema (HAE): analysis of frequency, characteristics, treatment and direct costs in 133 patients observed prospectively for one year
Authors: Francesca Perego, Valentina Crosta, Carlo Federici, Ludovica Borsoi, Andrea Zanichelli, Maddalena Alessandra Wu, Antonio Gidaro, Rosanna Tarricone, Marco Cicardi
Journal: Journal of Allergy and Clinical Immunology (2017)